Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 145Carcinoma, Non-Small-Cell Lung 97Colorectal Neoplasms 96Carcinoma, Hepatocellular 69Stomach Neoplasms 65Rectal Neoplasms 54Neoplasms 53Lung Neoplasms 44Prostatic Neoplasms 41Colonic Neoplasms 41Leukemia, Myeloid, Acute 40Nasopharyngeal Carcinoma 39Lymphoma, Large B-Cell, Diffuse 39Uterine Cervical Neoplasms 37Esophageal Neoplasms 33Ovarian Neoplasms 32Neoplasm Metastasis 32Multiple Myeloma 31Lymphoma 31Lymphoma, Follicular 30Leukemia 28Pancreatic Neoplasms 27Recurrence 23Head and Neck Neoplasms 22Brain Neoplasms 21Urinary Bladder Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Non-Hodgkin 19Lymphoma, Mantle-Cell 18Squamous Cell Carcinoma of Head and Neck 17

Interventions

amonafide 1Daunorubicin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Lymphatic Diseases × Clear all
NCT00715637 2010-10-13

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Antisoma Research

Phase 3 Unknown
420 enrolled
Other hematologic neoplasm

Leukemia, Lymphatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡